Previous Close | 49.33 |
1-Year Change | -19.36% |
6-Months Change | -2.08% |
3-Months Change | -16.35% |
Moving Avg (50d) | 65.828 |
Moving Avg (200d) | 58.383 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 8.92B |
Beta (3-Years) | 1.49 |
Revenue Growth (ttm) | 19.99% |
Net Profit Margin (ttm) | -11.73% |
Return On Assets (ttm) | -4.39% |
EPS (ttm) | -1.59 |
PE Ratio (ttm) | -31.03 |
Dividend Yield | % |
Asset Description: | Exact Sciences Corporation |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-10-01 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
51.852 | 50.264 | 49.206 | 47.619 | 44.973 | 42.328 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |
Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision... Wikipedia